Abstract A key strategy for precision therapy lies in identifying and targeting tumor cell-specific metabolic vulnerabilities to develop effective combination treatments. In this study, we demonstrate that vandetanib, a multi-kinase inhibitor, acts as a potent transcriptional repressor of the serine synthesis pathway (SSP) in non-small cell lung cancer (NSCLCs).
Fuhui Wang
As seen in:
Nature,
Wiley,
Wiley Online Library,
ScienceDirect,
Frontiers,
MDPI,
Anti-Corrosion Methods and Materials
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Fuhui
Contact Fuhui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack